Manuscripts and Publications

Filters: Keyword is Middle Aged  [Clear All Filters]
2019
Coy KC, Hazen RJ, Kirkham HS, Delpino A, Siegler AJ.  2019.  Persistence on HIV preexposure prophylaxis medication over a 2-year period among a national sample of 7148 PrEP users, United States, 2015 to 2017.. J Int AIDS Soc. 22(2):e25252.
2017
Mullins TLKowalczy, Zimet G, Lally M, Xu J, Thornton S, Kahn JA.  2017.  HIV Care Providers' Intentions to Prescribe and Actual Prescription of Pre-Exposure Prophylaxis to At-Risk Adolescents and Adults.. AIDS Patient Care STDS. 31(12):504-516.
2016
Castillo-Mancilla J, Seifert S, Campbell K, Coleman S, McAllister K, Zheng J-H, Gardner EM, Liu A, Glidden DV, Grant R et al..  2016.  Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing.. Antimicrob Agents Chemother. 60(11):6692-6697.
2015
Gilbert ALewis, Knopf AS, J Fortenberry D, Hosek SG, Kapogiannis BG, Zimet GD.  2015.  Adolescent Self-Consent for Biomedical Human Immunodeficiency Virus Prevention Research.. J Adolesc Health. 57(1):113-9.
Mullins TLKowalczy, Lally M, Zimet G, Kahn JA.  2015.  Clinician attitudes toward CDC interim pre-exposure prophylaxis (PrEP) guidance and operationalizing PrEP for adolescents.. AIDS Patient Care STDS. 29(4):193-203.
2011
Baheti G, Kiser JJ, Havens PL, Fletcher CV.  2011.  Plasma and intracellular population pharmacokinetic analysis of tenofovir in HIV-1-infected patients.. Antimicrob Agents Chemother. 55(11):5294-9.
2006
Turnbull EL, A Lopes R, Jones NA, Cornforth D, Newton P, Aldam D, Pellegrino P, Turner J, Williams I, Wilson CM et al..  2006.  HIV-1 epitope-specific CD8+ T cell responses strongly associated with delayed disease progression cross-recognize epitope variants efficiently.. J Immunol. 176(10):6130-46.